These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15918327)

  • 21. New developments in the management of hyperphosphatemia in chronic kidney disease.
    McIntyre CW
    Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More on the role of metabolic acidosis in causing uremic hyperphosphatemia.
    De Marchi S; Cecchin E
    Miner Electrolyte Metab; 1987; 13(1):67-8. PubMed ID: 3587185
    [No Abstract]   [Full Text] [Related]  

  • 23. Brain calcification due to secondary hyperparathyroidism in a child with chronic renal failure.
    Bilge I; Sadikoğlu B; Emre S; Sirin A; Tatli B
    Turk J Pediatr; 2005; 47(3):287-90. PubMed ID: 16250319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical factors in progressive renal injury. The role of hyperphosphatemia.
    Alfrey AC; Zhu JM
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):53-6. PubMed ID: 2024674
    [No Abstract]   [Full Text] [Related]  

  • 25. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical control of secondary hyperparathyroidism: we're not there yet.
    Goodman WG
    Kidney Int; 2004 Jan; 65(1):335-6. PubMed ID: 14675068
    [No Abstract]   [Full Text] [Related]  

  • 28. Extraosseous calcification in patients with chronic renal failure--no escape?
    Braun J
    Nephrol Dial Transplant; 2005 Oct; 20(10):2054-9. PubMed ID: 16077145
    [No Abstract]   [Full Text] [Related]  

  • 29. Most patients with coronary artery calcification have no coronary artery stenosis and hyperphosphatemia should be important in reevaluating the K/DOQI guidelines.
    Yokoyama K; Nishioka M; Sakuma T; Yoshida S; Iida R; Yoshida H; Hara S; Ohkido I; Katoh N; Yamamoto H; Shigematsu T; Nakayama M; Sherif AM; Fukuda K; Hosoya T
    Ther Apher Dial; 2006 Feb; 10(1):101. PubMed ID: 16556145
    [No Abstract]   [Full Text] [Related]  

  • 30. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digital clubbing as an unusual complication associated with severe secondary hyperparathyroidism: report of two cases.
    Grekas D; Avdelidou A
    Hemodial Int; 2007 Apr; 11(2):193-7. PubMed ID: 17403170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osmotic fragility of erythrocytes and secondary hyperparathyroidism in chronic renal failure.
    Docci D
    Nephron; 1987; 45(3):247-8. PubMed ID: 3574573
    [No Abstract]   [Full Text] [Related]  

  • 34. [The importance of acidosis and hyperphosphatemia on variations of the organic phosphor esters of the erythrocytes in chronic renal insufficiency].
    Quarto di Palo FM; Lanucara P; Gastaldi L; Ciconali M
    Haematol Lat; 1966; 9(4):349-57. PubMed ID: 5998728
    [No Abstract]   [Full Text] [Related]  

  • 35. Cephalometric evaluation of patients with Sagliker syndrome: uglifying human face appearance in severe and late secondary hyperparathyroidism in chronic renal failure patients.
    Uzel A; Uzel I; Sagliker Y; Yildiz I; Halvaci I; Paylar N; Ocal F; Balal M; Ozkaynak PS; Paydas S; Sagliker C; Sagliker HS; Kiralp N; Adam SM; Esenturk M; Gocmez E; Taskapan H; Yuksekgonul M; Emir I; Guler T; Yakar H; Sekin O; Kayali E; Caliskan S; Eskiocak AF; Ogruk B; Guzelyurt T; Kurt C
    J Ren Nutr; 2006 Jul; 16(3):229-32. PubMed ID: 16825025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperphosphatemia-induced hyperparathyroidism in 5/6 nephrectomized rats: development of a new animal model.
    Jiang Y; Wang M
    Chin Med J (Engl); 2008 Dec; 121(23):2440-3. PubMed ID: 19102965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A woman with chronic kidney failure, progressive calciphylaxis and sepsis].
    Svendsen EB; Christiansen R; Svarstad E; Aase S
    Tidsskr Nor Laegeforen; 2008 May; 128(11):1295-6. PubMed ID: 18546584
    [No Abstract]   [Full Text] [Related]  

  • 39. New therapies for uremic secondary hyperparathyroidism.
    Torres PU; Prié D; Beck L; Friedlander G
    J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of three formulations of calcium acetate tablets to evaluate tolerance and control of hyperphosphatemia in patients with chronic renal failure.
    van den Bergh JP; Kaufmann BG; van Riet GJ; Böttger WM; Verstappen VM
    Nephron; 1994; 68(4):505-6. PubMed ID: 7870237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.